Immunic, Inc. Common Stock (IMUX) Stock Price

IMUXStock
$15.40+77.01%52W
Market Cap$210.12M
P/E
PEG Ratio
Div yield
Beta1.40

IMUX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)59.56%
Price vs S&P 500 (4W)7.68%
VGM Score63.24

IMUX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$1.17-$0.80+31.33%(+$0.37)
Q1 2026-$0.96-$1.08-12.84%(-$0.12)
Q4 2025-$1.11-$0.70+37.00%(+$0.41)
Q3 2025-$1.90-$1.30+31.58%(+$0.60)
Q2 2025-$1.58-$2.00-26.32%(-$0.42)

IMUX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.36
4.38
4.38
4.38

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
IMUXImmunic, Inc. Common Stock
B$15.40
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Immunic, Inc. Common Stock

Immunic is a clinical-stage biopharmaceutical company developing selective oral therapies for chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. The company's pipeline includes three lead candidates: IMU-838 (immune cell metabolism inhibitor), IMU-935 (RORγt pathway modulator), and IMU-856 (intestinal barrier restoration). These therapies target large patient populations with significant unmet treatment needs.